Latest News

Big multiple sclerosis breakthrough: Phase 1 trial safely resets patients' immune systems and reduces attack on myelin protein

A phase 1 clinical trial for the first treatment to reset the immune system of multiple sclerosis (MS) patients showed the therapy was safe and dramatically reduced patients' immune systems' reactivity to myelin by 50 to 75 percent. The therapy used billions of patients' own specially processed blood cells to create tolerance to myelin, the insulating layer that forms around nerves. In MS, the immune system attacks myelin. The approach left the normal immune system intact.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • New therapeutic target may improve treatment for brain cancer

  • New compounds could offer therapy for multitude of diseases

  • Stem cells make similar decisions to humans

  • Why good solutions make us oblivious to better ones

  • When attention is a deficit: Sometimes a new strategy makes sense

  • Stereotypes lower math performance in women, but effects go unrecognized

  • For drivers with telescopic lenses, driving experience and training affect road test results

  • Will you ever pay off your student loan?

  • Public Health Responsibility Deal in UK unlikely to be an effective response to alcohol harms

  • Immunotherapy used to reduce memory problems with Alzheimer's disease

  •